UK markets open in 1 hour 30 minutes
  • NIKKEI 225

    28,940.87
    -247.30 (-0.85%)
     
  • HANG SENG

    28,954.79
    +199.45 (+0.69%)
     
  • CRUDE OIL

    61.88
    +0.45 (+0.73%)
     
  • GOLD FUTURES

    1,784.80
    +2.80 (+0.16%)
     
  • DOW

    33,815.90
    -321.41 (-0.94%)
     
  • BTC-GBP

    35,544.89
    -3,785.54 (-9.62%)
     
  • CMC Crypto 200

    1,114.54
    -128.51 (-10.34%)
     
  • ^IXIC

    13,818.41
    -131.81 (-0.94%)
     
  • ^FTAS

    3,965.04
    +29.40 (+0.75%)
     

Global Inductive Proximity Sensors Market to Reach $2.4 Billion by 2027

ReportLinker
·26-min read

Project Details: - StrategyR - A Trademark of Global Industry Analysts, Inc. - Project Edition: 5. - Influencer Pool: 423. - MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.

New York, March 30, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Humanized Mouse & Rat Model Industry" - https://www.reportlinker.com/p06041640/?utm_source=GNW
In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack.
- Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

  • Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.

  • Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.

  • Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.

  • Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations.

  • Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives.

Abstract:
- Global Humanized Mouse and Rat Model Market to Reach $176.8 Million by 2027
- Amid the COVID-19 crisis, the global market for Humanized Mouse and Rat Model estimated at US$100.9 Million in the year 2020, is projected to reach a revised size of US$176.8 Million by 2027, growing at aCAGR of 8.3% over the period 2020-2027. Humanized Mouse Models, one of the segments analyzed in the report, is projected to record 8.4% CAGR and reach US$165.8 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Humanized Rat Models segment is readjusted to a revised 6.8% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $27.3 Million, While China is Forecast to Grow at 11.1% CAGR
- The Humanized Mouse and Rat Model market in the U.S. is estimated at US$27.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$36.6 Million by the year 2027 trailing a CAGR of 11.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.6% and 7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

- Select Competitors (Total 44 Featured) -

  • Axenis S.A.S.

  • Charles River Laboratories International, Inc.

  • Crown Bioscience, Inc.

  • Genoway S.A.

  • Harbour Antibodies BV

  • Hera BioLabs

  • inGenious Targeting Laboratory, Inc.

  • Taconic Biosciences, Inc.

  • The Jackson Laboratory

  • Trans Genic, Inc.




Read the full report: https://www.reportlinker.com/p06041640/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Humanized Mouse &
Rat Model by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ for Years
2020 through 2027 and % CAGR

Table 2: World Historic Review for Humanized Mouse & Rat Model
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 3: World 15-Year Perspective for Humanized Mouse & Rat
Model by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2012,
2020 & 2027

Table 4: World Current & Future Analysis for Humanized Mouse
Models by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for Humanized Mouse Models by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 6: World 15-Year Perspective for Humanized Mouse Models
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Humanized Rat
Models by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Humanized Rat Models by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 9: World 15-Year Perspective for Humanized Rat Models by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Neuroscience by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 11: World Historic Review for Neuroscience by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Neuroscience by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Hematopoesis by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 14: World Historic Review for Hematopoesis by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Hematopoesis by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Oncology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 17: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Immunology &
Infectious Diseases by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Immunology & Infectious
Diseases by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Immunology & Infectious
Diseases by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 22: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 24: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Pharmaceutical &
Biotechnology Companies by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Pharmaceutical &
Biotechnology Companies by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Pharmaceutical &
Biotechnology Companies by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

Table 28: World Current & Future Analysis for CRO by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for CRO by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for CRO by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Academic &
Research Institutions by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Academic & Research
Institutions by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Academic & Research
Institutions by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 34: USA Current & Future Analysis for Humanized Mouse &
Rat Model by Type - Humanized Mouse Models and Humanized Rat
Models - Independent Analysis of Annual Sales in US$ for the
Years 2020 through 2027 and % CAGR

Table 35: USA Historic Review for Humanized Mouse & Rat Model
by Type - Humanized Mouse Models and Humanized Rat Models
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 36: USA 15-Year Perspective for Humanized Mouse & Rat
Model by Type - Percentage Breakdown of Value Sales for
Humanized Mouse Models and Humanized Rat Models for the Years
2012, 2020 & 2027

Table 37: USA Current & Future Analysis for Humanized Mouse &
Rat Model by Application - Neuroscience, Hematopoesis,
Oncology, Immunology & Infectious Diseases and Other
Applications - Independent Analysis of Annual Sales in US$ for
the Years 2020 through 2027 and % CAGR

Table 38: USA Historic Review for Humanized Mouse & Rat Model
by Application - Neuroscience, Hematopoesis, Oncology,
Immunology & Infectious Diseases and Other Applications Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 39: USA 15-Year Perspective for Humanized Mouse & Rat
Model by Application - Percentage Breakdown of Value Sales for
Neuroscience, Hematopoesis, Oncology, Immunology & Infectious
Diseases and Other Applications for the Years 2012, 2020 & 2027

Table 40: USA Current & Future Analysis for Humanized Mouse &
Rat Model by End-Use - Pharmaceutical & Biotechnology
Companies, CRO and Academic & Research Institutions -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027 and % CAGR

Table 41: USA Historic Review for Humanized Mouse & Rat Model
by End-Use - Pharmaceutical & Biotechnology Companies, CRO and
Academic & Research Institutions Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 42: USA 15-Year Perspective for Humanized Mouse & Rat
Model by End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, CRO and Academic &
Research Institutions for the Years 2012, 2020 & 2027

CANADA
Table 43: Canada Current & Future Analysis for Humanized Mouse &
Rat Model by Type - Humanized Mouse Models and Humanized Rat
Models - Independent Analysis of Annual Sales in US$ for the
Years 2020 through 2027 and % CAGR

Table 44: Canada Historic Review for Humanized Mouse & Rat
Model by Type - Humanized Mouse Models and Humanized Rat Models
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 45: Canada 15-Year Perspective for Humanized Mouse & Rat
Model by Type - Percentage Breakdown of Value Sales for
Humanized Mouse Models and Humanized Rat Models for the Years
2012, 2020 & 2027

Table 46: Canada Current & Future Analysis for Humanized Mouse &
Rat Model by Application - Neuroscience, Hematopoesis,
Oncology, Immunology & Infectious Diseases and Other
Applications - Independent Analysis of Annual Sales in US$ for
the Years 2020 through 2027 and % CAGR

Table 47: Canada Historic Review for Humanized Mouse & Rat
Model by Application - Neuroscience, Hematopoesis, Oncology,
Immunology & Infectious Diseases and Other Applications Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 48: Canada 15-Year Perspective for Humanized Mouse & Rat
Model by Application - Percentage Breakdown of Value Sales for
Neuroscience, Hematopoesis, Oncology, Immunology & Infectious
Diseases and Other Applications for the Years 2012, 2020 & 2027

Table 49: Canada Current & Future Analysis for Humanized Mouse &
Rat Model by End-Use - Pharmaceutical & Biotechnology
Companies, CRO and Academic & Research Institutions -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027 and % CAGR

Table 50: Canada Historic Review for Humanized Mouse & Rat
Model by End-Use - Pharmaceutical & Biotechnology Companies,
CRO and Academic & Research Institutions Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019 and
% CAGR

Table 51: Canada 15-Year Perspective for Humanized Mouse & Rat
Model by End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, CRO and Academic &
Research Institutions for the Years 2012, 2020 & 2027

JAPAN
Table 52: Japan Current & Future Analysis for Humanized Mouse &
Rat Model by Type - Humanized Mouse Models and Humanized Rat
Models - Independent Analysis of Annual Sales in US$ for the
Years 2020 through 2027 and % CAGR

Table 53: Japan Historic Review for Humanized Mouse & Rat Model
by Type - Humanized Mouse Models and Humanized Rat Models
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 54: Japan 15-Year Perspective for Humanized Mouse & Rat
Model by Type - Percentage Breakdown of Value Sales for
Humanized Mouse Models and Humanized Rat Models for the Years
2012, 2020 & 2027

Table 55: Japan Current & Future Analysis for Humanized Mouse &
Rat Model by Application - Neuroscience, Hematopoesis,
Oncology, Immunology & Infectious Diseases and Other
Applications - Independent Analysis of Annual Sales in US$ for
the Years 2020 through 2027 and % CAGR

Table 56: Japan Historic Review for Humanized Mouse & Rat Model
by Application - Neuroscience, Hematopoesis, Oncology,
Immunology & Infectious Diseases and Other Applications Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 57: Japan 15-Year Perspective for Humanized Mouse & Rat
Model by Application - Percentage Breakdown of Value Sales for
Neuroscience, Hematopoesis, Oncology, Immunology & Infectious
Diseases and Other Applications for the Years 2012, 2020 & 2027

Table 58: Japan Current & Future Analysis for Humanized Mouse &
Rat Model by End-Use - Pharmaceutical & Biotechnology
Companies, CRO and Academic & Research Institutions -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027 and % CAGR

Table 59: Japan Historic Review for Humanized Mouse & Rat Model
by End-Use - Pharmaceutical & Biotechnology Companies, CRO and
Academic & Research Institutions Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Humanized Mouse & Rat
Model by End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, CRO and Academic &
Research Institutions for the Years 2012, 2020 & 2027

CHINA
Table 61: China Current & Future Analysis for Humanized Mouse &
Rat Model by Type - Humanized Mouse Models and Humanized Rat
Models - Independent Analysis of Annual Sales in US$ for the
Years 2020 through 2027 and % CAGR

Table 62: China Historic Review for Humanized Mouse & Rat Model
by Type - Humanized Mouse Models and Humanized Rat Models
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 63: China 15-Year Perspective for Humanized Mouse & Rat
Model by Type - Percentage Breakdown of Value Sales for
Humanized Mouse Models and Humanized Rat Models for the Years
2012, 2020 & 2027

Table 64: China Current & Future Analysis for Humanized Mouse &
Rat Model by Application - Neuroscience, Hematopoesis,
Oncology, Immunology & Infectious Diseases and Other
Applications - Independent Analysis of Annual Sales in US$ for
the Years 2020 through 2027 and % CAGR

Table 65: China Historic Review for Humanized Mouse & Rat Model
by Application - Neuroscience, Hematopoesis, Oncology,
Immunology & Infectious Diseases and Other Applications Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 66: China 15-Year Perspective for Humanized Mouse & Rat
Model by Application - Percentage Breakdown of Value Sales for
Neuroscience, Hematopoesis, Oncology, Immunology & Infectious
Diseases and Other Applications for the Years 2012, 2020 & 2027

Table 67: China Current & Future Analysis for Humanized Mouse &
Rat Model by End-Use - Pharmaceutical & Biotechnology
Companies, CRO and Academic & Research Institutions -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027 and % CAGR

Table 68: China Historic Review for Humanized Mouse & Rat Model
by End-Use - Pharmaceutical & Biotechnology Companies, CRO and
Academic & Research Institutions Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Humanized Mouse & Rat
Model by End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, CRO and Academic &
Research Institutions for the Years 2012, 2020 & 2027

EUROPE
Table 70: Europe Current & Future Analysis for Humanized Mouse &
Rat Model by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 71: Europe Historic Review for Humanized Mouse & Rat
Model by Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 72: Europe 15-Year Perspective for Humanized Mouse & Rat
Model by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2012, 2020 & 2027

Table 73: Europe Current & Future Analysis for Humanized Mouse &
Rat Model by Type - Humanized Mouse Models and Humanized Rat
Models - Independent Analysis of Annual Sales in US$ for the
Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Humanized Mouse & Rat
Model by Type - Humanized Mouse Models and Humanized Rat Models
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 75: Europe 15-Year Perspective for Humanized Mouse & Rat
Model by Type - Percentage Breakdown of Value Sales for
Humanized Mouse Models and Humanized Rat Models for the Years
2012, 2020 & 2027

Table 76: Europe Current & Future Analysis for Humanized Mouse &
Rat Model by Application - Neuroscience, Hematopoesis,
Oncology, Immunology & Infectious Diseases and Other
Applications - Independent Analysis of Annual Sales in US$ for
the Years 2020 through 2027 and % CAGR

Table 77: Europe Historic Review for Humanized Mouse & Rat
Model by Application - Neuroscience, Hematopoesis, Oncology,
Immunology & Infectious Diseases and Other Applications Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 78: Europe 15-Year Perspective for Humanized Mouse & Rat
Model by Application - Percentage Breakdown of Value Sales for
Neuroscience, Hematopoesis, Oncology, Immunology & Infectious
Diseases and Other Applications for the Years 2012, 2020 & 2027

Table 79: Europe Current & Future Analysis for Humanized Mouse &
Rat Model by End-Use - Pharmaceutical & Biotechnology
Companies, CRO and Academic & Research Institutions -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027 and % CAGR

Table 80: Europe Historic Review for Humanized Mouse & Rat
Model by End-Use - Pharmaceutical & Biotechnology Companies,
CRO and Academic & Research Institutions Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019 and
% CAGR

Table 81: Europe 15-Year Perspective for Humanized Mouse & Rat
Model by End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, CRO and Academic &
Research Institutions for the Years 2012, 2020 & 2027

FRANCE
Table 82: France Current & Future Analysis for Humanized Mouse &
Rat Model by Type - Humanized Mouse Models and Humanized Rat
Models - Independent Analysis of Annual Sales in US$ for the
Years 2020 through 2027 and % CAGR

Table 83: France Historic Review for Humanized Mouse & Rat
Model by Type - Humanized Mouse Models and Humanized Rat Models
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 84: France 15-Year Perspective for Humanized Mouse & Rat
Model by Type - Percentage Breakdown of Value Sales for
Humanized Mouse Models and Humanized Rat Models for the Years
2012, 2020 & 2027

Table 85: France Current & Future Analysis for Humanized Mouse &
Rat Model by Application - Neuroscience, Hematopoesis,
Oncology, Immunology & Infectious Diseases and Other
Applications - Independent Analysis of Annual Sales in US$ for
the Years 2020 through 2027 and % CAGR

Table 86: France Historic Review for Humanized Mouse & Rat
Model by Application - Neuroscience, Hematopoesis, Oncology,
Immunology & Infectious Diseases and Other Applications Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 87: France 15-Year Perspective for Humanized Mouse & Rat
Model by Application - Percentage Breakdown of Value Sales for
Neuroscience, Hematopoesis, Oncology, Immunology & Infectious
Diseases and Other Applications for the Years 2012, 2020 & 2027

Table 88: France Current & Future Analysis for Humanized Mouse &
Rat Model by End-Use - Pharmaceutical & Biotechnology
Companies, CRO and Academic & Research Institutions -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027 and % CAGR

Table 89: France Historic Review for Humanized Mouse & Rat
Model by End-Use - Pharmaceutical & Biotechnology Companies,
CRO and Academic & Research Institutions Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019 and
% CAGR

Table 90: France 15-Year Perspective for Humanized Mouse & Rat
Model by End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, CRO and Academic &
Research Institutions for the Years 2012, 2020 & 2027

GERMANY
Table 91: Germany Current & Future Analysis for Humanized Mouse &
Rat Model by Type - Humanized Mouse Models and Humanized Rat
Models - Independent Analysis of Annual Sales in US$ for the
Years 2020 through 2027 and % CAGR

Table 92: Germany Historic Review for Humanized Mouse & Rat
Model by Type - Humanized Mouse Models and Humanized Rat Models
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 93: Germany 15-Year Perspective for Humanized Mouse & Rat
Model by Type - Percentage Breakdown of Value Sales for
Humanized Mouse Models and Humanized Rat Models for the Years
2012, 2020 & 2027

Table 94: Germany Current & Future Analysis for Humanized Mouse &
Rat Model by Application - Neuroscience, Hematopoesis,
Oncology, Immunology & Infectious Diseases and Other
Applications - Independent Analysis of Annual Sales in US$ for
the Years 2020 through 2027 and % CAGR

Table 95: Germany Historic Review for Humanized Mouse & Rat
Model by Application - Neuroscience, Hematopoesis, Oncology,
Immunology & Infectious Diseases and Other Applications Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 96: Germany 15-Year Perspective for Humanized Mouse & Rat
Model by Application - Percentage Breakdown of Value Sales for
Neuroscience, Hematopoesis, Oncology, Immunology & Infectious
Diseases and Other Applications for the Years 2012, 2020 & 2027

Table 97: Germany Current & Future Analysis for Humanized Mouse &
Rat Model by End-Use - Pharmaceutical & Biotechnology
Companies, CRO and Academic & Research Institutions -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027 and % CAGR

Table 98: Germany Historic Review for Humanized Mouse & Rat
Model by End-Use - Pharmaceutical & Biotechnology Companies,
CRO and Academic & Research Institutions Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019 and
% CAGR

Table 99: Germany 15-Year Perspective for Humanized Mouse & Rat
Model by End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, CRO and Academic &
Research Institutions for the Years 2012, 2020 & 2027

ITALY
Table 100: Italy Current & Future Analysis for Humanized Mouse &
Rat Model by Type - Humanized Mouse Models and Humanized Rat
Models - Independent Analysis of Annual Sales in US$ for the
Years 2020 through 2027 and % CAGR

Table 101: Italy Historic Review for Humanized Mouse & Rat
Model by Type - Humanized Mouse Models and Humanized Rat Models
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 102: Italy 15-Year Perspective for Humanized Mouse & Rat
Model by Type - Percentage Breakdown of Value Sales for
Humanized Mouse Models and Humanized Rat Models for the Years
2012, 2020 & 2027

Table 103: Italy Current & Future Analysis for Humanized Mouse &
Rat Model by Application - Neuroscience, Hematopoesis,
Oncology, Immunology & Infectious Diseases and Other
Applications - Independent Analysis of Annual Sales in US$ for
the Years 2020 through 2027 and % CAGR

Table 104: Italy Historic Review for Humanized Mouse & Rat
Model by Application - Neuroscience, Hematopoesis, Oncology,
Immunology & Infectious Diseases and Other Applications Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 105: Italy 15-Year Perspective for Humanized Mouse & Rat
Model by Application - Percentage Breakdown of Value Sales for
Neuroscience, Hematopoesis, Oncology, Immunology & Infectious
Diseases and Other Applications for the Years 2012, 2020 & 2027

Table 106: Italy Current & Future Analysis for Humanized Mouse &
Rat Model by End-Use - Pharmaceutical & Biotechnology
Companies, CRO and Academic & Research Institutions -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027 and % CAGR

Table 107: Italy Historic Review for Humanized Mouse & Rat
Model by End-Use - Pharmaceutical & Biotechnology Companies,
CRO and Academic & Research Institutions Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019 and
% CAGR

Table 108: Italy 15-Year Perspective for Humanized Mouse & Rat
Model by End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, CRO and Academic &
Research Institutions for the Years 2012, 2020 & 2027

UNITED KINGDOM
Table 109: UK Current & Future Analysis for Humanized Mouse &
Rat Model by Type - Humanized Mouse Models and Humanized Rat
Models - Independent Analysis of Annual Sales in US$ for the
Years 2020 through 2027 and % CAGR

Table 110: UK Historic Review for Humanized Mouse & Rat Model
by Type - Humanized Mouse Models and Humanized Rat Models
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 111: UK 15-Year Perspective for Humanized Mouse & Rat
Model by Type - Percentage Breakdown of Value Sales for
Humanized Mouse Models and Humanized Rat Models for the Years
2012, 2020 & 2027

Table 112: UK Current & Future Analysis for Humanized Mouse &
Rat Model by Application - Neuroscience, Hematopoesis,
Oncology, Immunology & Infectious Diseases and Other
Applications - Independent Analysis of Annual Sales in US$ for
the Years 2020 through 2027 and % CAGR

Table 113: UK Historic Review for Humanized Mouse & Rat Model
by Application - Neuroscience, Hematopoesis, Oncology,
Immunology & Infectious Diseases and Other Applications Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 114: UK 15-Year Perspective for Humanized Mouse & Rat
Model by Application - Percentage Breakdown of Value Sales for
Neuroscience, Hematopoesis, Oncology, Immunology & Infectious
Diseases and Other Applications for the Years 2012, 2020 & 2027

Table 115: UK Current & Future Analysis for Humanized Mouse &
Rat Model by End-Use - Pharmaceutical & Biotechnology
Companies, CRO and Academic & Research Institutions -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027 and % CAGR

Table 116: UK Historic Review for Humanized Mouse & Rat Model
by End-Use - Pharmaceutical & Biotechnology Companies, CRO and
Academic & Research Institutions Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 117: UK 15-Year Perspective for Humanized Mouse & Rat
Model by End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, CRO and Academic &
Research Institutions for the Years 2012, 2020 & 2027

SPAIN
Table 118: Spain Current & Future Analysis for Humanized Mouse &
Rat Model by Type - Humanized Mouse Models and Humanized Rat
Models - Independent Analysis of Annual Sales in US$ for the
Years 2020 through 2027 and % CAGR

Table 119: Spain Historic Review for Humanized Mouse & Rat
Model by Type - Humanized Mouse Models and Humanized Rat Models
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 120: Spain 15-Year Perspective for Humanized Mouse & Rat
Model by Type - Percentage Breakdown of Value Sales for
Humanized Mouse Models and Humanized Rat Models for the Years
2012, 2020 & 2027

Table 121: Spain Current & Future Analysis for Humanized Mouse &
Rat Model by Application - Neuroscience, Hematopoesis,
Oncology, Immunology & Infectious Diseases and Other
Applications - Independent Analysis of Annual Sales in US$ for
the Years 2020 through 2027 and % CAGR

Table 122: Spain Historic Review for Humanized Mouse & Rat
Model by Application - Neuroscience, Hematopoesis, Oncology,
Immunology & Infectious Diseases and Other Applications Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 123: Spain 15-Year Perspective for Humanized Mouse & Rat
Model by Application - Percentage Breakdown of Value Sales for
Neuroscience, Hematopoesis, Oncology, Immunology & Infectious
Diseases and Other Applications for the Years 2012, 2020 & 2027

Table 124: Spain Current & Future Analysis for Humanized Mouse &
Rat Model by End-Use - Pharmaceutical & Biotechnology
Companies, CRO and Academic & Research Institutions -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027 and % CAGR

Table 125: Spain Historic Review for Humanized Mouse & Rat
Model by End-Use - Pharmaceutical & Biotechnology Companies,
CRO and Academic & Research Institutions Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019 and
% CAGR

Table 126: Spain 15-Year Perspective for Humanized Mouse & Rat
Model by End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, CRO and Academic &
Research Institutions for the Years 2012, 2020 & 2027

RUSSIA
Table 127: Russia Current & Future Analysis for Humanized Mouse &
Rat Model by Type - Humanized Mouse Models and Humanized Rat

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06041640/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001